Skip to main content

Table 2 Effect of IL-1β treatment in in vitro chondrosarcoma culture

From: In vitro suppression of the MMP-3 gene in normal and cytokine-treated human chondrosarcoma using small interfering RNA

  48 h   72 h  
  Non-IL1 IL-1 Non-IL1 IL-1
Cell morphology     
Viability rate 93.05 ± 4.23 46.41 ± 6.04* 93.87 ± 3.44 26.52 ± 5.97*
Apoptosis rate 2.28 ± 1.71 63.39 ± 11.43* 4.62 ± 1.72 70.73 ± 5.02*
Mitotic rate 9.42 ± 2.43 1.36 ± 0.90* 16.22 ± 7.62 0.85 ± 0.30*
Proteoglycan production    
HA (ng/ml) 121.04 ± 23.03 48.54 ± 12.85* 146.04 ± 11.93 35.29 ± 8.54*
GAG (μg/ml) 1.91 ± 0.88 0.56 ± 0.14* 1.72 ± 0.81 0.17 ± 0.07*
Relative gene expression    
MMP-3 0.98 ± 0.07 2.03 ± 0.23* 1.56 ± 0.18 2.94 ± .019*
TIMP-3 1.01 ± 0.03 0.57 ± 0.21* 1.35 ± 0.09 0.34 ± 0.06*
HAS-1 1.02 ± 0.13 0.37 ± 0.15* 1.35 ± 0.10 0.15 ± 0.07*
HAS-2 1.02 ± 0.11 0.10 ± 0.04* 1.18 ± 0.12 0.05 ± 0.04*
AGG 1.01 ± 0.06 0.43 ± 0.18* 1.35 ± 0.10 0.17 ± 0.03*
COL2A1 1.02 ± 0.11 0.15 ± 0.10* 1.48 ± 0.14 0.03 ± 0.08*
  1. A significant difference (p < 0.05) between treatment and non-treatment with IL-1β at the same period (48 or 72 h) is displayed with superscript (*) on the number.